Full Text

Turn on search term navigation

© 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Introduction

Infants born very preterm (VPT, <32 weeks’ gestation) are at increased risk for neurodevelopmental impairments including motor, cognitive and behavioural delay. Parents of infants born VPT also have poorer mental health outcomes compared with parents of infants born at term.

We have developed an intervention programme called TEDI-Prem (Telehealth for Early Developmental Intervention in babies born very preterm) based on previous research. TEDI-Prem aims to improve neurodevelopmental outcomes and parental well-being in children born VPT. Here we present the protocol outlining a multicentre, pragmatic, parallel-group, randomised controlled trial to determine the efficacy of TEDI-Prem plus usual care, compared with usual care alone.

Methods and analysis

We will recruit 466 VPT infants from the neonatal units of five hospitals in Victoria, Australia. Participants will be randomised, stratified by site of recruitment and multiple births, to TEDI-Prem plus usual care or usual care alone. The TEDI-Prem intervention programme involves 13 sessions across three phases. Phase 1 commences in the neonatal unit with four face-to-face sessions with parent/s and a physiotherapist/occupational therapist. Once discharged from the hospital, sessions across phases 2 and 3 (six and three sessions, respectively) continue via telehealth until infants are 12 months’ corrected age (CA).

The primary outcome is the Bayley Scales of Infant and Toddler Development-fourth edition (Bayley-4) Motor Composite Score at 12 months’ CA. Secondary outcomes address other neurodevelopmental domains (Bayley-4 cognitive and language composite score; Infant Toddler Social Emotional Assessment), parental mental health (Depression Anxiety and Stress Scale 21), parent–child interaction (Emotional Availability Scale) and programme cost-effectiveness which encompasses parent quality of life (Short-Form Six-Dimension Quality of Life) and child quality of life (EuroQol Toddler and Infant Populations measure) at 12 and 24 months’ CA.

Mean differences between groups will be examined using linear regression for continuous outcomes and logistic regression for binary outcomes. All models will be fitted via generalised estimating equations to account for multiple births and adjusted for the hospital sites.

Ethics and dissemination

This trial has Royal Children’s Hospital Human Research and Ethics Committee approval (HREC/67604/RCHM-2020) with specific site approval for all participating sites. Findings will be disseminated through peer-reviewed publications, conference presentations, digital and print media and to participants.

Trial egistration number

This trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621000364875).

Details

Title
Protocol for a multisite randomised controlled trial assessing the effect of the Telehealth for Early Developmental Intervention in babies born very preterm (TEDI-Prem) programme on neurodevelopmental outcomes and parent well-being
Author
Eeles, Abbey L 1   VIAFID ORCID Logo  ; Spittle, Alicia J 1   VIAFID ORCID Logo  ; Dusing, Stacey 2 ; Anderson, Peter J 3 ; Brown, Shaaron 4 ; Dalziel, Kim 5   VIAFID ORCID Logo  ; Fehring, Susan M 6 ; Henty, Gillian 1 ; Holland, Anne E 7 ; Huang, Li 8   VIAFID ORCID Logo  ; Hunt, Rod W 9 ; Kozaris, Elizabeth 10 ; Lee, Katherine 11 ; Morgan, Angela T 12   VIAFID ORCID Logo  ; Schembri, Rachel 13 ; Treyvaud, Karli 14 

 Department of Physiotherapy, University of Melbourne, Melbourne, Victoria, Australia; Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria, Australia; The Royal Women's Hospital, Melbourne, Victoria, Australia 
 Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, California, USA 
 Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria, Australia; School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia; Department of Paediatrics, School of Medicine, University of California Irvine, Irvine, California, USA; Turner Institute for Brain & Mental Health, Monash University, Melbourne, Victoria, Australia 
 Department of Physical Therapy, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA 
 Health Economics Unit, Centre for Health Policy, University of Melbourne, Melbourne, Victoria, Australia 
 Department of Physiotherapy, University of Melbourne, Melbourne, Victoria, Australia; Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria, Australia; The Royal Women's Hospital, Melbourne, Victoria, Australia; Department of Physiotherapy, Western Health, Melbourne, Victoria, Australia 
 Department of Physiotherapy, Alfred Health, Melbourne, Victoria, Australia; Department of Allergy, Immunology and Respiratory Medicine, Central Clnical School, The Alfred Hospital, Monash University, Melbourne, Victoria, Australia 
 Health Economics unit, University of Melbourne Centre for Health Policy, Melbourne, Victoria, Australia 
 Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Dept of Paediatrics, Monash University, Melbourne, Victoria, Australia; Cerebral Palsy Alliance Research Institute, Sydney, New South Wales, Australia 
10  The Royal Women's Hospital, Melbourne, Victoria, Australia; Monash Children's Hospital, Melbourne, Victoria, Australia 
11  Clinical Epidemiology & Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia 
12  Speech and Language, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia; Department of Speech Pathology, University of Melbourne, Melbourne, Victoria, Australia; Speech Pathology, The Royal Children’s Hospital, Melbourne, Victoria, Australia 
13  Clinical Epidemiology and Biostatistics, Melbourne Children's Trials Centre, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia 
14  Clinical Sciences, Murdoch Children's Research Institute, Melbourne, Victoria, Australia; Department of Psychology, Counselling and Therapy, La Trobe University, Melbourne, Victoria, Australia 
First page
e086904
Section
Paediatrics
Publication year
2024
Publication date
2024
Publisher
BMJ Publishing Group LTD
e-ISSN
20446055
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3147676892
Copyright
© 2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.